These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29206243)

  • 1. Corrigendum: Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
    Chen W; Shui F; Liu C; Zhou X; Li W; Zheng Z; Fu W; Wang L
    Front Pharmacol; 2017; 8():890. PubMed ID: 29206243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
    Chen W; Shui F; Liu C; Zhou X; Li W; Zheng Z; Fu W; Wang L
    Front Pharmacol; 2017; 8():707. PubMed ID: 29051736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
    Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
    FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice.
    Chang CP; Wu CH; Song JS; Chou MC; Wong YC; Lin Y; Yeh TK; Sadani AA; Ou MH; Chen KH; Chen PH; Kuo PC; Tseng CT; Chang KH; Tseng SL; Chao YS; Hung MS; Shia KS
    J Med Chem; 2013 Dec; 56(24):9920-33. PubMed ID: 24224693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum.
    Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
    Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
    Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
    Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
    Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
    Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
    Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.
    Tam J; Szanda G; Drori A; Liu Z; Cinar R; Kashiwaya Y; Reitman ML; Kunos G
    Mol Metab; 2017 Oct; 6(10):1113-1125. PubMed ID: 29031713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity.
    Han JH; Shin H; Rho JG; Kim JE; Son DH; Yoon J; Lee YJ; Park JH; Song BJ; Choi CS; Yoon SG; Kim IY; Lee EK; Seong JK; Kim KW; Kim W
    Diabetes Obes Metab; 2018 Sep; 20(9):2179-2189. PubMed ID: 29740969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diet-Induced Obesity in Cannabinoid-2 Receptor Knockout Mice and Cannabinoid Receptor 1/2 Double-Knockout Mice.
    Alshaarawy O; Kurjan E; Truong N; Olson LK
    Obesity (Silver Spring); 2019 Mar; 27(3):454-461. PubMed ID: 30699233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Matthews JM; McNally JJ; Connolly PJ; Xia M; Zhu B; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5346-5349. PubMed ID: 27671496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
    Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J
    Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
    Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
    Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid CB
    Argueta DA; Perez PA; Makriyannis A; DiPatrizio NV
    Front Physiol; 2019; 10():704. PubMed ID: 31281260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.
    Hjorth S; Karlsson C; Jucaite A; Varnäs K; Wählby Hamrén U; Johnström P; Gulyás B; Donohue SR; Pike VW; Halldin C; Farde L
    Neuropharmacology; 2016 Feb; 101():519-30. PubMed ID: 25791528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.